Management of chronic obstructive pulmonary disease in the Middle East and North Africa: Results of the BREATHE study - 04/01/13
on behalf of the BREATHE Study GroupB
Summary |
Chronic obstructive pulmonary disease (COPD) is a potentially severe chronic progressive respiratory condition requiring long-term treatment and frequently involving episodic hospitalisations to manage exacerbations. The objective of this analysis was to document diagnosis, evaluation, treatment and management of COPD-related respiratory symptoms in 1,392 subjects fulfilling an epidemiological definition of COPD identified in a general population sample of 62,086 individuals aged ≥ 40 years in ten countries in the Middle East and North Africa region (Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Syria, Tunisia, Turkey and United Arab Emirates), together with Pakistan. 442 subjects (31.8%) claimed to have received a diagnosis of COPD from a physician and 287 (20.6%) had undergone spirometry in the previous year. Use of specific treatments for respiratory symptoms was reported by 218 subjects (15.7%). Use of inhaled long-acting bronchodilators together with corticosteroids (53 subjects; 3.8%) and use of oxygen therapy (31 subjects; 2.3%) was very low. 852 subjects (61.2%) had consulted a physician about their respiratory condition at least once in the previous year, with a mean number of consultations of 3.4±3.6. Moreover, 284 subjects (20.4%) had been hospitalised overnight for their COPD, with a mean of 2.3±3.7 hospitalisations per year. Use of all healthcare resources was significantly higher (p < 0.001) in subjects with CAT scores ≥10 than in those with scores < 10, and greater in those with exacerbations than in those without. In conclusion, COPD in the region is under-diagnosed, inadequately evaluated and inadequately treated. Nonetheless, COPD symptoms are responsible for considerable healthcare consumption, with high levels of physician consultation and hospitalisation.
Le texte complet de cet article est disponible en PDF.Keywords : COPD, Management, Middle East, North Africa, Diagnosis, Treatment
Plan
Conflict of interest statement MI has received honoraria from GlaxoSmithKline Laboratories for his contribution to the BREATHE study and has received speaking honoraria from AstraZeneca, Novartis, Sanofi, MSD, Pfizer, Actelion and Bayer. M-LK, ST, NS, MP, ABK, AA, GI, AK and AJ have received honoraria from GlaxoSmithKline Laboratories for their contribution to the BREATHE study. NR and AEH are employees of GlaxoSmithKline Laboratories, which funded the BREATHE study and market a number of treatments for COPD. |
Vol 106 - N° S2
P. S33-S44 - décembre 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?